Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion
Fortrea acquires Worldwide Clinical Trials' Early Phase division for $45 million in cash to expand its clinical research network.
Fortrea bought a smaller company's early-stage research business for $45 million to grow bigger and help more drug companies test new medicines. When companies buy other businesses to get stronger, watch if they can blend their teams smoothly and keep customers happy.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.